Adagio Medical Reports Strong FULCRUM-VT Trial Results, Expands FDA Trial
Event summary
- FULCRUM-VT trial results show 84% freedom from ICD shock at six months, 2.4% major adverse events, and 72% reduction in antiarrhythmic drug use.
- FDA approved expansion of FULCRUM-VT trial for next-generation vCLAS Ultra System.
- Pre-clinical results published in Journal of Cardiovascular Electrophysiology show titratable lesion depth exceeding 10mm and 50-75% reduction in ablation time.
- Completed 13 cases under FDA Expanded Access using vCLAS System in patients with recurrent VT.
- Reported $12.9M in cash and cash equivalents as of March 31, 2026, with potential for up to $31M additional gross proceeds.
The big picture
Adagio Medical's strong FULCRUM-VT trial results position it as a leader in catheter ablation technologies for treating cardiac arrhythmias. The FDA's approval to expand the trial for the next-generation vCLAS Ultra System underscores the company's strategic focus on advancing its Ultra-Low Temperature Ablation platform. The broader industry trend towards more effective and safer treatments for ventricular tachycardia highlights Adagio's potential to capture significant market share.
What we're watching
- Clinical Validation
- Whether the FULCRUM-VT trial results can be replicated and lead to FDA premarket approval for the vCLAS Cryoablation System.
- Regulatory Pathway
- The pace at which Adagio can advance its next-generation vCLAS Ultra System through the FDA approval process.
- Financial Sustainability
- How Adagio will manage its cash position and potential additional gross proceeds to support its clinical and commercial activities.